On May 5, 2023 Araris Biotech AG ("Araris" or "the Company"), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, reported that, Innosuisse, the Swiss innovation agency committed to promote science-based innovation in the interest of the economy and society in Switzerland, has supported Araris with CHF 2.5M non-dilutive grant funding through the Swiss Accelerator program for the development and advancement of its ADC candidates (Press release, Araris Biotech, MAY 5, 2023, View Source [SID1234651281]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Innosuisse Swiss Accelerator grant provides an opportunity for Swiss SMEs and start-ups to receive direct financial support for innovation projects with significant potential. Innosuisse received 752 project applications. Out of those, 53 projects were selected for approval after a three-stage assessment process. The Swiss Accelerator program’s total funding grant amounted to CHF 112M (~$125 million) with support per project amounting to a maximum of CHF 2.5M (~$2.8 million).
"We are honored to have been selected for the Swiss Accelerator grant and grateful to receive this support from Innosuisse," said Philipp Spycher, Ph.D., chief executive officer and co-founder of Araris Biotech. "This non-dilutive funding will be beneficial as we continue to develop and advance our pipeline of next-generation ADC candidates, developed using our proprietary linker technology, towards the clinic."
Araris’ ADC linker technology enables payload attachment to off the shelf antibodies without needing to re-engineer or reduce antibodies, resulting in highly homogenous, stable and potent ADC therapies. It also has the potential to address challenges associated with current ADCs, including unstable linkage, which can result in toxicity issues or lack of efficacy.